Who makes Abrocitinib Suspension F5?

Abrocitinib Suspension F5 is developed by Pfizer Inc..

What development phase is Abrocitinib Suspension F5 in?

Abrocitinib Suspension F5 is in Phase 1.

What are the side effects of Abrocitinib Suspension F5?

Common side effects include Nausea, Incision site complication, Headache, Dyspepsia, Vomiting, Hunger.

What is the generic name of Abrocitinib Suspension F5?

abrocitinib-suspension-f5 is the generic (nonproprietary) name of Abrocitinib Suspension F5.

Last reviewed 2026-04-20 · How we verify

Abrocitinib Suspension F5 (abrocitinib-suspension-f5)

Pfizer Inc. · Phase 1 active Quality 10/100

At a glance

Generic name	abrocitinib-suspension-f5
Sponsor	Pfizer Inc.
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Nausea
Incision site complication
Headache
Dyspepsia
Vomiting
Hunger
Pruritus
Ear pain
Diarrhoea
Feeling abnormal
Vessel puncture site haematoma
Vessel puncture site pain

Key clinical trials

A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Abrocitinib Suspension F5 CI brief — competitive landscape report
Abrocitinib Suspension F5 updates RSS · CI watch RSS
Pfizer Inc. portfolio CI